Gynecomastia does not directly cause breast cancer, but it is associated with a significantly higher risk. A large pooled study from the National Cancer Institute found that gynecomastia, independent from other known risk factors like obesity and Klinefelter syndrome, was linked to a 10-fold increased risk of breast cancer in men. That sounds alarming, but context matters: male breast cancer is extremely rare, with a lifetime risk of about 1 in 755. Even a tenfold increase keeps the absolute risk low for any individual man.
Why the Link Exists
Gynecomastia and male breast cancer share a common underlying driver: a shift in the balance between estrogen and testosterone. When estrogen activity outweighs androgen activity at the breast tissue level, glandular tissue in the male breast begins to grow. This ductal growth is what creates the firm, disc-like tissue behind the nipple that characterizes gynecomastia.
That same hormonal environment, sustained over time, may create conditions more favorable for cancerous changes. It’s not that the benign tissue itself transforms into cancer. Rather, the hormonal imbalance that produced gynecomastia in the first place also raises the probability that abnormal cells could develop. Think of gynecomastia as a visible signal that the hormonal conditions associated with male breast cancer are present, not as a direct stepping stone to malignancy.
Shared Risk Factors to Know About
Several conditions push estrogen levels up or testosterone levels down, contributing to both gynecomastia and an elevated breast cancer risk. Obesity is one of the most common. Fat tissue contains an enzyme that converts androgens into estrogen, so higher body fat means more estrogen circulating in the body. Klinefelter syndrome, a genetic condition where men carry an extra X chromosome, causes both low testosterone and higher estrogen, substantially raising the risk of both conditions. Chronic liver disease and hyperthyroidism can also shift the hormonal balance by changing how the body handles sex hormones.
Genetic mutations play a role as well. Men who carry a harmful BRCA2 gene change have a 1.8% to 7.1% chance of developing breast cancer by age 70, compared to 0.1% in the general male population. BRCA1 changes carry a smaller but still elevated risk of 0.2% to 1.2%. These mutations don’t cause gynecomastia directly, but men with a family history of breast or ovarian cancer should be aware that their baseline risk is already higher.
Do Medications That Cause Gynecomastia Also Raise Cancer Risk?
Many medications can trigger gynecomastia by interfering with hormone levels. These include certain prostate drugs, heart medications like spironolactone, and anti-androgen therapies. A natural concern is whether drug-induced gynecomastia carries the same cancer risk as other forms.
The evidence so far is reassuring. A large epidemiological study looked specifically at a class of prostate drugs called 5-alpha reductase inhibitors, which are known to increase gynecomastia rates. The study found that while these drugs did significantly raise the risk of developing gynecomastia, they did not increase the risk of breast cancer compared to unexposed men. The hormonal disruption from short-term or medication-related causes appears to be different from the chronic, endogenous imbalance that drives the cancer association.
How Gynecomastia Feels Different From a Tumor
The physical characteristics of gynecomastia and breast cancer are quite distinct. Gynecomastia typically presents as a soft, tender, mobile mass centered directly behind the nipple on both sides. It often feels rubbery or firm and you can usually move it with your fingers. It tends to be symmetrical, though one side can be larger than the other.
A cancerous lump in the male breast behaves differently. It’s usually hard, painless, and fixed in place rather than mobile. It tends to appear off-center rather than directly beneath the nipple, and it’s almost always on one side only. Skin changes like dimpling, retraction of the nipple, or bloody discharge from the nipple are red flags that point away from simple gynecomastia and toward something that needs urgent evaluation.
When Imaging Is Recommended
If your doctor examines you and the findings are consistent with typical gynecomastia (bilateral, soft, centered behind the nipple), current guidelines from the American College of Radiology say no imaging is routinely needed. The clinical exam alone is usually enough to make the diagnosis.
Imaging becomes important when something looks or feels atypical. Unilateral breast growth that can’t be explained, a hard or fixed mass, or any suspicious features on exam will prompt a mammogram and often an ultrasound. Because the male breast has limited volume, mammography can be technically challenging, so ultrasound has become an increasingly important tool. If any doubt remains after imaging, an ultrasound-guided biopsy can provide a definitive answer. The key takeaway is that routine cancer screening isn’t necessary for straightforward gynecomastia, but any unusual changes deserve prompt attention.
Putting the Numbers in Perspective
The 10-fold relative risk increase from gynecomastia is real, but relative risk can be misleading without context. A man’s baseline lifetime risk of breast cancer is about 0.13%. Even multiplied by 10, that puts the absolute risk somewhere around 1%. For comparison, the lifetime risk of breast cancer in women is about 13%, or roughly 1 in 8. So a man with gynecomastia, even with the elevated risk, still faces a far lower probability than the average woman.
That said, the rarity of male breast cancer is itself a risk factor for late diagnosis. Because men don’t expect to get breast cancer, lumps are often ignored longer, leading to later-stage diagnoses. If you have gynecomastia and notice a change in how the tissue feels, particularly a new hard spot, asymmetry that wasn’t there before, or skin changes, getting it checked promptly makes a meaningful difference in outcomes.